Pharmaceuticals 13 March 2026 - 26 May 2026

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote
·······

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote

Ligand Pharmaceuticals shares moved higher on Tuesday. The stock outperformed biotech funds, which took a hit, as investors focused on upcoming management meetings and stayed active trading Ligand’s pending XOMA Royalty deal. The Nasdaq-listed stock was trading at $233.11 as of 12:53 p.m. EDT, up 1.4%. The SPDR S&P Biotech ETF was down 3.8% and the iShares Nasdaq Biotechnology ETF slid 3.0%. The SPY ETF, which tracks the S&P 500, edged up 0.1% and the QQQ, which follows the Nasdaq 100, added 0.4%.
June 2, 2026
Lexaria Gets Attention with GLP-1 Test on Deck
····

Lexaria Gets Attention with GLP-1 Test on Deck

Lexaria Bioscience Corp. will open for normal Nasdaq trading on Tuesday after closing Friday at $0.65. Shares climbed 7.33% in the last full session before the Memorial Day holiday. Regular trading restarts at 9:30 a.m. Eastern, with pre-market open at 4 a.m. Lexaria’s move is now in focus as its next test takes aim at the fast-growing oral obesity drug space. GLP-1 medicines that copy a gut hormone for hunger and blood sugar are a big market, dominated by Novo Nordisk and Eli Lilly.
May 26, 2026
60 Degrees Pharma Nears FDA Deadline in Thin Holiday Trading
····

60 Degrees Pharma Nears FDA Deadline in Thin Holiday Trading

60 Degrees Pharmaceuticals Inc. goes into Tuesday with shares at $1.48, unchanged during a quiet session as U.S. stock markets closed Monday for Memorial Day. Investors are watching for a possible update as an FDA notification deadline falls the same day. According to the Nasdaq holiday calendar, markets were closed May 25, with usual trading hours set for 9:30 a.m. to 4 p.m. ET on standard days. No Monday tape and thin trading could hit the next move in SXTP. The stock dipped 0.7% Friday with 49,620 shares trading. Still, SXTP climbed 6.5% over the week, moving from $1.39 last Friday to $1.48 at the May 22 close.
May 25, 2026
CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes
····

CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes

CervoMed Inc. shares head into the long U.S. market weekend under pressure, with CRVO ending Friday at $3.06 and down about 11% for the week after a first-quarter update shifted attention back to funding for its planned late-stage dementia trial. That matters now because Nasdaq is closed on Monday for Memorial Day, leaving Tuesday as the next regular session for investors to trade on the update. The pause comes after a rough week for the small-cap biotech, even as broader U.S. indexes finished higher.
May 23, 2026
GPCR Stock Jumps As Obesity-Drug Race Gets A New Twist
·····

GPCR Stock Jumps As Obesity-Drug Race Gets A New Twist

Structure Therapeutics Inc. shares rose 5.3% to $38.79 in late New York trading on Thursday, outpacing the broader biotech tape as investors kept the drug developer in the obesity-pill trade. The stock touched $38.85, with volume of about 499,000 shares. The move came with no new company release in the past two days. That matters because the next real test for Structure is not a same-day headline, but whether aleniglipron, its experimental oral GLP-1 drug, can move cleanly into Phase 3 and hold up against larger rivals.
May 21, 2026
Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders
····

Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders

Bright Minds Biosciences Inc. shares climbed on Wednesday after Piper Sandler boosted its price target on the company. DRUG closed at $82.78 on the Nasdaq, jumping 11.1% from Tuesday’s $74.54 finish. The new target puts the stock in focus for Thursday’s U.S. trading. That’s relevant since U.S. markets were still closed at the dateline. Regular hours at Nasdaq are 9:30 a.m. to 4:00 p.m. Eastern, with pre-market hours ahead of that. So Wednesday’s close was the last official mark.
May 21, 2026
Why Revelation Biosciences Stock Jumped Today as Traders Eye Its Kidney-Drug Bet
····

Why Revelation Biosciences Stock Jumped Today as Traders Eye Its Kidney-Drug Bet

Revelation Biosciences shares were quoted at $1.09 after the U.S. market close on Wednesday, up $0.06, or 5.82%, giving the clinical-stage biotech a market value of about $4.1 million. The move beat a firmer Nasdaq session, with the broader index up about 1.55% late in the day. The gain was not a catch-up trade after a holiday. Nasdaq’s 2026 calendar lists Memorial Day on May 25 as the next U.S. market closure, leaving Wednesday as a regular trading session for REVB.
May 20, 2026
GSK Stock Goes Ex-Dividend Today: Why the 17p Payout Comes With a Bigger Pipeline Test
····

GSK Shares Face Monday Test After Dividend Hit, China Drug Deal And Buyback

GSK’s shares slipped into the weekend, leaving Monday’s session as an early test of whether investors still want to buy the drugmaker after a China pipeline deal and a fresh buyback push, or whether the stock remains capped by dividend and earnings-quality concerns. The stock closed Friday at 1,862.5 pence, down 10p, or 0.53%, with the day’s range stretching from 1,855.5p to 1,899.5p. It was still up from 1,843p a week earlier, helped by a sharp Tuesday gain, but the move was not clean. Volume on Friday was 11.08 million shares, above several sessions earlier in the week.
May 16, 2026
GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus
·····

GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus

GSK plc is pushing for wider access to bepirovirsen in China, locking in an exclusive deal with Chia Tai Tianqing Pharmaceutical, part of Sino Biopharmaceutical. With this move, the British pharma giant aims to turn its late-stage hepatitis B candidate into a serious growth engine. CTTQ is set to manage import, distribution, hospital access, and promotion across mainland China. GSK, for its part, keeps a grip on regulatory and medical strategy. Timing’s key here. Bepirovirsen is on the investor radar as GSK pushes to move past its traditional vaccine and HIV drug business, aiming to top £40 billion in yearly sales by 2031—a goal it stuck with after posting £7.6 billion for the first quarter. Last month, Chief Executive Luke
May 13, 2026
GSK Wins Paxil Trademark Fight in India, But Its Bigger Test Is Still Ahead
····

GSK Wins Paxil Trademark Fight in India, But Its Bigger Test Is Still Ahead

Glaxo Group Limited, under the GSK Group umbrella, secured a Bombay High Court decision this day requiring Shreya Life Sciences Private Limited to cancel its registration of the Paxil trademark in India—a notable brand victory for GSK plc and its popular medicine. The dispute focused on Shreya’s lack of use of the mark in actual pharmaceutical products. The court's decision lands at a time when GSK faces scrutiny over whether new CEO Luke Miels can defend sales, speed up drug development, and handle looming patent cliffs. Shares dropped last week despite a first-quarter beat—traders picked over the numbers and flagged issues beneath the surface. “Quality concerns around the earnings beat,” Verso Investment Management analyst James Eugene noted, pointing to non-recurring
May 4, 2026
GSK Stock Gets Fresh Catalyst as UK Clears Lynavoy and Pipeline Pressure Builds
···

GSK Stock Gets Fresh Catalyst as UK Clears Lynavoy and Pipeline Pressure Builds

The UK’s Medicines and Healthcare products Regulatory Agency has signed off on GSK plc’s Lynavoy for adult patients with primary biliary cholangitis, giving the pharma giant another regulatory nod in liver disease—right after it passed the drug along to Alfasigma. The approval, granted to GlaxoSmithKline UK Limited, marks what interim executive director of healthcare quality and access Julian Beach described as a “new treatment option” for those with PBC. Timing’s crucial. GSK wants to reassure investors about its pipeline as it faces mounting pressure from aging drugs and the 2028 patent cliff on dolutegravir, its flagship HIV medicine. Still, shares tumbled following first-quarter numbers this week. Earnings did come in ahead of forecasts, but Verso Investment Management analyst James Eugene
May 1, 2026
GSK plc’s Jemperli Court Fight With AnaptysBio Takes New Turn Before July Trial
···

GSK plc’s Jemperli Court Fight With AnaptysBio Takes New Turn Before July Trial

Tesaro, GSK plc’s U.S. oncology arm, saw a setback in its Delaware case over Jemperli—part of its claim against AnaptysBio was tossed. The court dismissed Tesaro’s anticipatory breach argument. GSK, though, noted that the main dispute over the contract is still in play, and Tesaro’s request for declaratory judgment remains. Timing’s key here. GSK is set to deliver first-quarter 2026 numbers on Wednesday, April 29, with investors zeroed in on whether oncology will keep doing the heavy lifting as older segments of the portfolio come under strain.
April 27, 2026
GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake
·······

GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake

GSK plc wrapped up changes to ViiV Healthcare’s ownership structure on April 1. After Pfizer’s exit from the HIV-focused joint venture, Japan’s Shionogi bumped its stake up to 21.7%. GSK remains the majority owner with 78.3%, the company said. Timing is crucial here: ViiV is a core growth driver as GSK shifts focus toward specialty medicines. For 2025, GSK reported an 11% increase in HIV sales to 7.7 billion pounds, fueling a 17% jump in specialty medicines revenue.
April 2, 2026
GSK plc Completes ViiV Healthcare Shake-Up as Pfizer Exits, Shionogi Lifts Stake
···

GSK plc Completes ViiV Healthcare Shake-Up as Pfizer Exits, Shionogi Lifts Stake

GSK on Wednesday wrapped up changes to the structure of its HIV unit ViiV Healthcare. Japan’s Shionogi raised its stake to 21.7% as Pfizer exited the partnership entirely. GSK retains a majority holding at 78.3%. Timing is crucial here. HIV remains a cornerstone for GSK, and Chief Executive Luke Miels is gunning for annual sales topping 40 billion pounds by 2031. For 2025, GSK reported HIV sales up 11% to 7.7 billion pounds. Miels is eyeing 2026 as a launch-heavy stretch, promising quicker development cycles and sharper operational focus.
April 1, 2026
GSK plc wins China approval for Exdensur as hepatitis B drug bepirovirsen enters review
···

GSK plc wins China approval for Exdensur as hepatitis B drug bepirovirsen enters review

London, March 30, 2026, 14:08 BST. GSK notched up two regulatory milestones in China on Monday: the country gave the green light to Exdensur, its asthma therapy, and kicked off a formal review for bepirovirsen, a hepatitis B hopeful. According to a company filing, Exdensur is now approved in China for severe eosinophilic asthma in patients 12 and up. The bepirovirsen filing covers chronic hepatitis B in adults, GSK said.
March 30, 2026
GSK Stock Rises as EMA Review of Bepirovirsen Lifts 2026 Approval Prospects
···

GSK Stock Rises as EMA Review of Bepirovirsen Lifts 2026 Approval Prospects

GSK shares picked up on Friday, trading at roughly 2,056 pence by 13:47 in London, a 0.54% gain, after the company announced the European Medicines Agency is set to review bepirovirsen, its investigational chronic hepatitis B therapy. The filing is significant—GSK has highlighted bepirovirsen as one of just two major product approvals it’s counting on for 2026, a year when the company has projected revenue growth will drop to between 3% and 5%, after hitting 7% in 2025. For CEO Luke Miels, the drug is part of the slate of new therapies he needs to offset looming patent expiries in GSK’s HIV portfolio.
March 27, 2026
GSK Stock Rises 2% as Japan Grants Orphan Status to Lung Cancer Drug
···

GSK Stock Rises 2% as Japan Grants Orphan Status to Lung Cancer Drug

GSK shares finished Tuesday up 2.07% at 1,977 pence, beating out the FTSE 100’s 0.72% gain. The move came after the British pharma firm announced that Japan had granted orphan-drug status to its investigational lung cancer therapy, risvutatug rezetecan. This shift comes at a crucial moment: investors want to see GSK deliver on its promise to push new drugs through the pipeline, as Chief Executive Luke Miels races to boost development and line up fresh medicines before patents run out in the HIV segment. “We need to accelerate what we have,” Miels said back in February, outlining a strategy that leans on brisker R&D and targeted acquisitions.
March 24, 2026
GSK Stock Slips After FDA Nod for Lynavoy Unlocks $100 Million Milestone
···

GSK Stock Slips After FDA Nod for Lynavoy Unlocks $100 Million Milestone

GSK shares edged lower Friday, shedding 0.28% to close at 1,950.5 pence in London. This came just a day after the UK pharmaceutical giant secured U.S. approval for Lynavoy, a new therapy targeting severe itch caused by a rare liver condition. This green light triggers a $100 million payout to GSK from Italy’s Alfasigma, as laid out in their March 9 licensing agreement. Alfasigma will assume global rights to develop, produce, and market the drug, shifting GSK’s role to collecting milestone checks and royalties based on future sales—not full revenue from the product.
March 20, 2026
GSK Stock Price Today: Shares Rise After FDA Approval of Lynavoy for Rare Liver-Disease Itch
···

GSK Stock Price Today: Shares Rise After FDA Approval of Lynavoy for Rare Liver-Disease Itch

GSK shares trading in the U.S. edged up 0.6% to $52.39 as of 3:59 p.m. EDT on Thursday. The move followed news that the FDA cleared Lynavoy, the company’s new treatment for severe itching in patients with primary biliary cholangitis, or PBC—a rare autoimmune liver disorder. GSK gets the green light at a crucial time. With patent cliffs approaching for its top HIV drugs, new CEO Luke Miels is under pressure to prove the company can bring fresh therapies to market. Lynavoy's approval marks the first liver treatment from GSK's pipeline to clear regulators, the company said.
March 19, 2026
GSK Stock Climbs as FDA Widens Arexvy RSV Shot to High-Risk Adults 18-49
···

GSK Stock Climbs as FDA Widens Arexvy RSV Shot to High-Risk Adults 18-49

GSK shares climbed Friday after the U.S. FDA cleared a broader use for its RSV vaccine, Arexvy, now including at-risk adults aged 18 to 49. The London-listed stock gained roughly 1.1%, trading near 2,054 pence, Reuters reported. This shift comes as GSK scrambles for new vaccine momentum at a time when that segment’s outlook has grown shakier. Just last month, the company warned investors that vaccine and general medicines revenue in 2026 might slip a bit or hold steady. Specialty medicines, by contrast, are still on track for stronger gains.
March 13, 2026
1 2 3 4